How Can Fluvoxamine Help in COVID-19 Treatment?
Aside from treating psychological disorders, fluvoxamine has also shown promise in clinical studies and trials on coronavirus treatment.
In a preliminary study, researchers from the Washington University School of Medicine in St. Louis discovered that the drug fluvoxamine appears to prevent severe symptoms and further complications of COVID-19 in patients with mild-to-moderate symptoms.
The results showed that patients did not develop breathing difficulties compared to other patients who did not receive the drug. Also, among those who took fluvoxamine, patients were less likely to require hospitalization. They were able to recover in the comfort of their own homes.
According to Dr. Caline Mattar, an assistant professor of medicine in the Division of Diseases, the goal of the study was to help patients recover at home without the need for hospital treatments and interventions. She said that fluvoxamine has been working well to achieve that goal.
Another study revealed that there is a link to fluvoxamine’s mechanism of action concerning the progression of COVID-19 in the early stage of the disease. The sigma-1 receptor found in the drug plays multiple roles in inflammation, platelet aggregation, as well as antiviral activities. The data also suggests that patients did not have to be hospitalized for any difficulties in lung function. However, despite the promising data we currently have, we still need further research and studies to establish the benefit of this drug for patients who has SARS-CoV-2 infection.
Fluvoxamine can bring a wide variety of benefits, traditionally as a treatment for psychological disorders, and now as a possible treatment for COVID-19. However, more research needs to be done. So before considering this drug, it is best to discuss the course of management with your doctor.
Learn more about Coronavirus here.